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Background:Nicotinicreceptorsareactivatedbyacetylcholineandhavebeenimplicatedinseveralneurologicaldisorders.
Results: Allosteric modulators, sharing close chemical similarity, exhibit five distinct pharmacological effects on 7 nicotinic
receptors.
Conclusion: Small changes in chemical structure have profound effects on the pharmacological properties of allosteric
modulators.
Significance: These findings may provide opportunities for novel approaches to therapeutic drug discovery.
Activationofnicotinicacetylcholinereceptors(nAChRs)isasso-
ciated with the binding of agonists such as acetylcholine to an ex-
tracellularsitethatislocatedattheinterfacebetweentwoadjacent
receptor subunits. More recently, there has been considerable in-
terest in compounds, such as positive and negative allosteric mod-
ulators(PAMsandNAMs),thatareabletomodulatenAChRfunc-
tion by binding to distinct allosteric sites. Here we examined a
series of compounds differing only in methyl substitution of a sin-
gle aromatic ring. This series of compounds includes a previously
described 7-selective allosteric agonist, cis-cis-4-p-tolyl-3a,
4,5,9b-tetrahydro-3H-cyclopenta[c]quinoline-8-sulfonamide (4MP-
TQS), together with all other possible combinations of methyl
substitutionataphenylring(18additionalcompounds).Studies
conducted with this series of compounds have revealed five dis-
tinct pharmacological effects on 7 nAChRs. These five effects
canbesummarizedas:1)nondesensitizingactivation(allosteric
agonists), 2) potentiation associated with minimal effects on re-
ceptordesensitization(typeIPAMs),3)potentiationassociated
withreduceddesensitization(typeIIPAMs),4)noncompetitive
antagonism (NAMs), and 5) compounds that have no effect on
orthosteric agonist responses but block allosteric modulation
(silent allosteric modulators (SAMs)). Several lines of experi-
mentalevidenceareconsistentwithallofthesecompoundsact-
ing at a common, transmembrane allosteric site. Notably, all of
thesechemicallysimilarcompoundsthathavebeenclassifiedas
nondesensitizing allosteric agonists or as nondesensitizing
(type II) PAMs are cis-cis-diastereoisomers, whereas all of the
NAMs, SAMs, and type I PAMs are cis-trans-diastereoisomers.
Our data illustrate the remarkable pharmacological diversity of
allosteric modulators acting on nAChRs.
Nicotinic acetylcholine receptors (nAChRs)
5 are cation-se-
lective ion channels that belong to the Cys loop superfamily of
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otherCysloopreceptors,nAChRsarepentamericcomplexesin
whichfivetransmembranesubunitsco-assembletoformacen-
tral ion channel (2, 3). Although all nAChRs share a similar
three-dimensional structure (4, 5), there is considerable diver-
sity in their subunit composition. For example, in mammalian
species, there are 16 nAChR subunits (1–7, 9, 10, 1–4,
, , and ) that can co-assemble to generate a diverse family of
nAChR subtypes (6, 7). In addition, some nAChR subunits
(such as 7) form functional homomeric nAChRs, containing
five copies of the same subunit (8). The human 7 nAChR has
beenidentifiedasapotentialtargetfortherapeuticdrugdiscov-
ery and has been implicated in a number of neurological and
psychiatricdisorders(9–13).The7nAChRissomewhatatyp-
ical of this receptor family, in that it undergoes very rapid
desensitization in response to activation by its endogenous
neurotransmitter acetylcholine (8). However, allosteric modu-
lation can facilitate activation of 7 nAChRs with only low lev-
els of desensitization (14–17).
Activation of nAChRs and the opening of the cation-selec-
tive pore is associated with the binding of agonists such as ace-
tylcholine to an orthosteric binding site located in the extracel-
lular domain of the receptor at the interface between two
adjacent subunits (18, 19). In addition, a range of compounds
have been identified that can modulate nAChR activation by
bindingtodistinctallostericsites(20)andmayhavepotentialas
novel approaches to therapeutic drug discovery (21). An area
that has attracted considerable interest concerns compounds
that lack intrinsic agonist activity on nAChRs but are able to
potentiate agonist-evoked responses by binding to a distinct
allostericsite.Suchcompoundshavebeendescribedaspositive
allosteric modulators (PAMs) and include compounds such as
TQS,aPAMthatdisplaysselectivityfor7nAChRs(15).Inthe
case of rapidly desensitizing nAChRs such as 7, PAMs have
been classified as being either type I or type II, depending on
whether they cause little or no effect on the rate of agonist-
induced desensitization (type I PAMs) or cause a reduction in
desensitization (type II PAMs) (20, 22, 23). In addition, there is
evidence that the binding of ligands to allosteric sites on
nAChRs can result in efficient activation of nAChRs in the
absence of orthosteric agonists (17, 24). In the case of 7
nAChRs, there is evidence for PAMs and allosteric agonists
bindingtoanintrasubunitcavitylocatedwithinthetransmem-
brane domain (17, 25, 26).
We have shown previously that minor changes in the chem-
icalstructureofnAChRallostericmodulatorscanresultindra-
matic differences in pharmacological properties (17, 24). For
example, replacing a fluorine atom with a chlorine atom con-
verts an 7-selective PAM into an allosteric agonist (24). The
presentstudyextendsthesefindings,withtheaimofidentifying
the influence of changes in chemical structure on the pharma-
cologicalpropertiesofnAChRallostericmodulators.Aseriesof
compounds, differing only in methyl substitution of a single
aromatic ring, have been examined (see Fig. 1). This series
includes an 7-selective allosteric agonist, 4MP-TQS, a com-
poundthathasbeenexaminedpreviously(24),togetherwithall
other possible combinations of methyl substitutions at a single
phenyl ring (18 additional compounds). The influence of
changes in chemical structure has been examined on 7
nAChRs by means of two-electrode voltage-clamp recording
and radioligand binding. Whereas previous studies of com-
pounds with close chemical similarity to TQS have identified
only allosteric agonists or type II PAMs (15, 17, 24), studies
conducted with this series of 19 methyl-substituted com-
pounds have revealed five distinct pharmacological effects on
7 nAChRs. In summary, the 19 methyl-substituted com-
pounds examined in this study can be classified in one of five
categories: allosteric agonists, type I PAMs, type II PAMs, neg-
ative allosteric modulators (NAMs), or silent allosteric modu-
lators (SAMs).
EXPERIMENTAL PROCEDURES
ChemicalSynthesis—Nineteencompoundsweresynthesized
that differed only in the pattern of methyl substitution of an
aromatic substituent located at position 2 of a tetrahydroiso-
quinolinering(seeFig.1).CompoundswerepreparedbyInCl3-
catalyzed reaction of sulfanilamide, cyclopentadiene, and the
corresponding substituted benzaldehyde, according to meth-
ods described previously (27). The substituted benzaldehydes
were either purchased commercially or prepared according to
literature procedures (28). In most cases (13 of the 19 com-
pounds), the cis-cis-diastereoisomer was obtained as the major
product from the InCl3-catalyzed multicomponent reaction
(see Fig. 1). However, in some cases (6 of the 19 compounds),
the cis-trans-diastereoisomer was obtained as the major prod-
uct (see Fig. 1). For all cis-trans-isomers and for two of the
cis-cis-isomers, only a single diastereoisomer was detected by
1H NMR. Further details concerning the synthesis of these
compounds and the major diastereoisomer obtained for each
compound, together with the ratio of isomers present in the
purified sample, are provided in the supplemental materials.
Subunit cDNAs and Plasmid Expression Vectors—Several
plasmid constructs used in this study have been described pre-
viously. These constructs include plasmids containing human
wild-type and mutant (M253L) nAChR 7 subunit cDNA con-
structsinplasmidpSP64GL(17,29),human7nAChRinplas-
mid pcDNA3 (30), mouse 5-HT3A in plasmid pRK5 (31), and
Caenorhabditis elegans RIC-3 in plasmid pRK5 (32).
Xenopus laevis Oocyte Electrophysiology—Oocytes were iso-
lated from female X. laevis and defolliculated as described pre-
viously(33).Heterologousexpressionwasachievedbyinjection
of either cRNA (6–12 ng) into oocyte cytoplasm in the case of
wild-typeandmutated7orplasmidcDNAconstructs(10–30
ng) into oocyte nuclei in the case of 5-HT3A. In vitro transcrip-
tion of cRNA was carried out using mMESSAGE mMACHINE
SP6transcriptionkit(Ambion,Huntington,UK).Oocyteswere
injected in a volume of 32.2 nl using a Drummond variable
volume microinjector. Two electrode voltage-clamp record-
ingswereperformed(withtheoocytemembranepotentialheld
at 60 mV), as described previously (33) using a Warner
Instruments OC-725C amplifier (Harvard Apparatus, Eden-
bridge, UK), PowerLab 8SP, and Chart 5 software (AD Instru-
ments, Oxford, UK). Methyl-TQS compounds were dissolved
in DMSO to generate 100 mM stock solutions. Compounds
were applied to oocytes using a BPS-8 solenoid valve solution
exchange system (ALA Scientific Inc., Westbury, NY), con-
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activation rates, statistical significance was determined with a
one-way analysis of variance (ANOVA). Statistical significance
of desensitization rates was determined by paired Student’s t
tests. A p value of 0.05 was considered significant. The acti-
vation and desensitization phases of current responses were
best fitted by a single exponential function.
CellCulture—HumankidneytsA201cellswereculturedinDul-
becco’s modified Eagle’s medium (Invitrogen) containing 10%
fetal calf serum (Sigma-Aldrich), penicillin (100 units/ml), and
streptomycin(100g/ml)(Invitrogen).Cellsweremaintainedina
humidified incubator containing 5% CO2 at 37 °C. Cells were co-
transfected with human 7 nAChR cDNA and C.elegans RIC-3
cDNA using Effectene reagent (Qiagen) according to the manu-
facturer’s instructions. After overnight incubation in Effectene,
cellswereincubatedat37 °Cfor24–48hbeforebeingassayedfor
radioligand binding.
RadioligandBinding—Radioligandbindingtotransientlytrans-
fectedtsA201cellswasperformedasdescribedpreviously(30,34)
with [
3H]-bungarotoxin (specific activity, 56 Ci/mmol; Tocris
Bioscience). Transfected cells were resuspended in Hank’s buff-
eredsalinesolution(Invitrogen)containing1%bovineserumalbu-
min and incubated with [
3H]-bungarotoxin for2ha t2 2° Ci na
totalvolumeof150l.Nonspecificbindingwasdeterminedinthe
presenceofmethyllycaconitine(MLA)(1M).Competitionbind-
ing experiments were performed by incubating triplicate samples
of transfected cells with [
3H]-bungarotoxin (10 nM), together
with a range of concentrations (1–100 M) of 2,3,6MP-TQS or
2,6MP-TQS and 100 M of all other allosteric modulators in this
study. Radioligand binding was assayed by filtration onto What-
man GF/A filters (presoaked in 0.5% polyethylenimine), followed
by rapid washing with phosphate-buffered saline (Oxoid) using a
Brandelcellharvester.Boundradioligandwasdeterminedbyscin-
tillation counting.
RESULTS
Nineteen compounds were synthesized that share close chem-
ical similarity to one another but form a series containing all pos-
siblecombinationsofmethylsubstitutiononasinglearomaticring
(Fig. 1). The majority of these compounds were obtained as the
cis-cis-diastereoisomerbutwithvaryingdegreesofdiastereoselec-
tivity (Fig. 1). However, those compounds containing an aromatic
ring bearing two ortho methyl groups were obtained as the cis-
trans-isomer with very high selectivity (Fig. 1). The pharmacolog-
ical properties of all 19 compounds were examined on human 7
nAChRs expressed in Xenopus oocytes.
Allosteric Agonist Activation of 7 nAChRs—Of the 19 methyl-
substituted compounds examined, seven of these (2,3MP-TQS,
2,3,4MP-TQS, 2,3,4,5MP-TQS, 2,4MP-TQS, 3,4MP-TQS,
3,4,5MP-TQS, and 4MP-TQS) were found to have properties
typical of 7 nAChR allosteric agonists (Fig. 2). In contrast to
the rapidly desensitizing responses observed with orthosteric
agonistssuchasacetylcholine,allsevenofthesemethyl-substi-
tuted compounds activated 7 nAChRs with very much
reduced levels of desensitization (Fig. 2B). Activation by the
methyl-substitutedcompoundsresultedinresponsesthatwere
similar to responses with allosteric agonists of 7 nAChRs
examined previously (17, 24, 35). Responses had a slow onset,
were slow to reach a plateau, and had very different kinetics to
activation by acetylcholine, which causes rapid desensitization
(Fig. 2B). Agonist activation rates were analyzed from the start
of agonist application to the peak response (Fig. 2A and Table
1). The rate of activation by all of the allosteric agonists exam-
ined was significantly slower compared with activation by ace-
tylcholine (p  0.01; Table 1). In addition, two of the allosteric
agonists (3,4MP-TQS and 4MP-TQS) had significantly slower
activationratesthantheotherfiveallostericagonists(p0.05;
Table 1).
Concentration-response curves were generated for three of the
seven allosteric agonists (2,3,4MP-TQS, 2,4MP-TQS, and 4MP-
TQS; Fig. 2C). As was observed with 7-selective allosteric ago-
nistsexaminedpreviously(17,24,35),concentrationsof2,3,4MP-
TQS, 2,4MP-TQS, and 4MP-TQS that caused half-maximal
activation of 7 nAChR were significantly lower than that of the
endogenous orthosteric agonist, acetylcholine (Table 1). In addi-
tion, concentration-response curves for 2,3,4MP-TQS, 2,4MP-
TQS,and4MP-TQSweresignificantlysteeperthanforacetylcho-
line (Table 1).
Type I and Type II Positive Allosteric Modulation of 7 nAChRs—
Forthose compounds that did not have allosteric agonist activ-
ity, their ability to potentiate or inhibit acetylcholine-induced
responses was examined. Potentiation of acetylcholine-evoked
responses was observed with eight of the twelve compounds
that lacked agonist activity (2MP-TQS, 2,3,4,6MP-TQS,
2,3,5MP-TQS, 2,4,5MP-TQS, 2,5MP-TQS, 3MP-TQS, 3,5MP-
TQS, and PentaMP-TQS; Figs. 3A and 4A and Table 2). The
lack of intrinsic agonist activity of these compounds, together
withtheirabilitytopotentiateacetylcholine-inducedresponses
is characteristic of a group of compounds that have been
described as PAMs (20).
None of the PAMs examined had a significant influence on the
rateofreceptoractivationcomparedwithacetylcholinealone.Al-
though the activation rates did not differ, differences were
observed in the rate of desensitization of 7 nAChRs with these
PAMs, as has been described previously with other PAMs (24).
Twoofthecompounds(2,3,4,6MP-TQSandPentaMP-TQS)dis-
played properties characteristic of type I PAMs, having no signifi-
cant difference on the rate of receptor desensitization compared
with acetylcholine (p  0.05; Fig. 3A and Table 2). The other six
compounds (2MP-TQS, 2,3,5MP-TQS, 2,4,5MP-TQS, 2,5MP-
TQS, 3MP-TQS, and 3,5MP-TQS) caused significant slowing in
the rate of receptor desensitization compared with acetylcholine
(p0.05; Fig. 4Aand Table 2), a property that is characteristic of
type II PAMs.
Concentration-responsecurvesweregeneratedwiththetwo
type I PAMs (2,3,4,6MP-TQS and PentaMP-TQS; Fig. 3B) and
with three of the six type II PAMs (2MP-TQS, 2,3,5MP-TQS
and 3,5MP-TQS; Fig. 4B). With PentaMP-TQS, a bell-shaped
concentration-response curve was observed (Fig. 4B). The
potentiating component of the concentration-response curve
with PentaMP-TQS produced a half-maximal potentiation at a
concentration of 0.55  0.36 M, although the true potency is
likely to be obscured by the inhibitory component of the con-
centration-response curve. A maximal potentiation of 2.4 
0.3-fold of the control acetylcholine response was observed
at 10 M PentaMP-TQS (Fig. 3B). Concentration-response
AllostericModulationof7NicotinicReceptors
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3B),andahalf-maximalpotentiationwasobservedataconcen-
trationof9.12.0M.Concentration-dependentpotentiation
of acetylcholine responses was seen for all three type II PAMs
examined (2MP-TQS, 2,3,5MP-TQS, and 3,5MP-TQS; Fig. 4B
and Table 2), with levels of potentiation of up to 39  7.5-fold
(Table 2).
Negative Allosteric Modulation of 7 nAChRs—Two of the
methyl-substituted compounds (2,3,6MP-TQS and 2,6MP-
TQS) caused inhibition of responses evoked by acetylcholine
on human 7 nAChRs (Fig. 5, A and B). This inhibition was
concentration-dependent (IC50  23  2.8 and 43  14 M for
2,3,6MP-TQS and 2,6MP-TQS, respectively). The maximum
inhibition of an EC50 concentration of acetylcholine (100 M)
that was observed was 68  2.8% with 2,3,6MP-TQS and 74 
4.2% with 2,6MP-TQS (Fig. 5B). In addition to their antagonist
effects on acetylcholine, 2,3,6MP-TQS and 2,6MP-TQS both
acted as antagonists when co-applied with allosteric agonists.
For example, a complete block of the response to the allosteric
agonist 2,4MP-TQS (applied at 10 M) was observed when co-
applied with 100 M of either 2,3,6MP-TQS or 2,6MP-TQS
(Fig.5A).Aplausibleexplanationfortheseeffectsmightbethat
2,3,6MP-TQS and 2,6MP-TQS were acting as noncompetitive
antagonists with respect to acetylcholine but binding at the
same site as the allosteric agonists. In contrast to the effects of
MLA as a competitive antagonist of acetylcholine (17), antago-
nism by 2,3,6MP-TQS and 2,6MP-TQS was not surmountable
(Fig. 5C) and had no significant effect on the EC50 value com-
pared with acetylcholine alone (EC50  120  32 and 104  27
M for 2,3,6MP-TQS and 2,6MP-TQS, respectively). This fea-
ture is characteristic of noncompetitive antagonism and sup-
ports the conclusion that 2,3,6MP-TQS and 2,6MP-TQS bind
at a site that is distinct from the conventional orthosteric bind-
ing site.
Silent Allosteric Modulators of 7 nAChRs—The remaining
two compounds in the series of 19 methyl-substituted com-
pounds(2,3,5,6MP-TQSand2,4,6MP-TQS)displayednoobvi-
ous pharmacological effects on 7 nAChRs, either when
applied alone (i.e. no evidence of allosteric agonist activation;
Fig. 6A) or when co-applied with acetylcholine (i.e. no PAM or
FIGURE1.Chemicalstructuresof7nAChRallostericmodulators.Onthebasisofexperimentaldataobtainedinthepresentstudy,compoundshavebeen
classified as allosteric agonists, desensitizing (type I) PAMs, nondesensitizing (type II) PAMs, NAMs, or SAMs. Compounds differ only in the pattern of methyl
substitutionatasinglearomaticring(designatedArinthefigure).Informationconcerningtheratioofcis-cis-andcis-trans-diastereoisomersobtainedduring
synthesis is provided in the supplemental materials.
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compounds was co-applied with an allosteric agonist (2,4MP-
TQS), both caused an inhibition of allosteric agonist activity
(Fig.6B).Co-applicationof2,4,6MP-TQSresultedinaconcen-
tration-dependent inhibition of responses evoked by 2,4MP-
FIGURE 3. Pharmacological properties of type I PAMs on 7 nAChRs
expressedinX. laevisoocytes.A,representativerecordingsareshownillus-
trating responses to the application of acetylcholine (100 M) alone or to a
maximal concentration of the PAM (PentaMP-TQS 10 M; 2,3,4,6MP-TQS 100
M)preappliedfor10sandthenco-appliedwithacetylcholine(100M).Solid
horizontal lines indicate the application of acetylcholine, and dotted horizon-
tal lines indicate the application of the PAM. B, concentration-response data
are presented for a range of concentrations of 2,3,4,6MP-TQS (open dia-
monds) and PentaMP-TQS (open circles) on responses evoked by a submaxi-
mal(EC50)concentrationofacetylcholinewithwild-type7nAChRs.ThePAM
waspreappliedfor10sandthenco-appliedwithacetylcholine(100M).Data
aremeansS.E.ofatleastthreeindependentexperiments,eachfromdiffer-
ent oocytes. Data are normalized to a submaximal (EC50) concentration of
acetylcholine (100 M).
TABLE1
Pharmacological and kinetic properties of 7 nAChR agonists
Data are means of 3–15 independent experiments  S.E. EC50 values of all com-
pounds examined were significantly different from that of acetylcholine (ANOVA
and Dunnett’s post hoc multiple comparison test; p  0.01). For all compounds
examined, Hill coefficients (nH) were significantly different from that of acetylcho-
line (ANOVA and Dunnett’s post hoc multiple comparison test; p  0.05). Activa-
tion rates correspond to the time constant for activation () in the continuous
presence of the agonist (ANOVA and Tukey’s post-hoc test: a versus b/c, p  0.01,
bversusc,p0.05).Maximumcurrentresponses(Imax)arepresentedasfoldeffects
in which responses to allosteric agonists have been normalized to the mean
response to a maximal concentration of acetylcholine (3 mM) obtained from the
same oocyte. ND, not determined.
Agonist EC50 nH
Activation
rate  Imax
M s Fold effect
Acetylcholine 128  12 1.3  0.2 0.22  0.11
a 1
2,3MP-TQS ND ND 14  2.4
b 2.7  2.1
2,3,4MP-TQS 9.8  0.8 2.7  0.9 9.4  0.9
b 12  2.7
2,3,4,5MP-TQS ND ND 6.4  1.0
b 4.9  0.4
2,4MP-TQS 11  1.0 2.8  0.6 7.5  0.4
b 16  5.1
3,4MP-TQS ND ND 29  4.2
c 7.8  3.0
3,4,5MP-TQS ND ND 7.2  0.6
b 2.6  1.0
4MP-TQS 27  3.1 2.2  0.2 25  2.4
c 8.7  1.3
FIGURE 2. Pharmacological properties of allosteric agonists on 7
nAChRs expressed in X. laevis oocytes. A, bar graph illustrating agonist
responses observed with 100 M of each compound. Responses are normal-
ized to the average response obtained upon application of acetylcholine
aloneatamaximumeffectiveconcentration(3mM).DataaremeansS.E.of
3–15 independent experiments (Table 1). B, representative recordings are
shownillustratingresponsestotheapplicationofacetylcholine(3mM)andof
the allosteric agonists (100 M). The horizontal lines indicate the duration
of agonist applications. Responses have been normalized to their peak
response. C, concentration-response data are presented for a range of con-
centrationsof2,3,4MP-TQS(opensquares),2,4MP-TQS(opencircles),4MP-TQS
(opendiamonds),andacetylcholine(closedcircles).DataaremeansS.E.ofat
least three independent experiments, each from different oocytes. Data are
normalized to agonist-induced responses induced by the maximal effective
concentration.
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2,3,5,6MP-TQS (100 M) with the allosteric agonist, 2,4MP-
TQS(10M)alsoresultedinafullblockoftheagonistresponse
with 2,4MP-TQS (Fig. 6B). A plausible explanation of these
effects would be that 2,3,5,6MP-TQS and 2,4,6MP-TQS are
binding at the same site as the allosteric agonists and causing
inhibition by displacement of the allosteric agonist from its
transmembrane binding site.
Influence of the Transmembrane L247T Mutation—Muta-
tions of amino acid Leu-247 (such as L247T) in 7 nAChRs
have been found to have dramatic effects on the functional
properties of the receptor (36). The L247T mutation causes
somecompetitiveantagoniststoactasagonists(37),anditalso
causes some PAMs, such as TQS, to act as agonists (17). The
influence of the L247T mutation was examined on those com-
pounds that displayed no agonist activity and neither potenti-
ated nor inhibited acetylcholine-evoked responses (2,3,5,6MP-
TQS and 2,4,6MP-TQS). Interestingly, it was found that the
L247T mutation converts both 2,3,5,6MP-TQS and 2,4,6MP-
TQS, which are silent allosteric modulators on wild-type 7
nAChRs,intoweaknondesensitizingagonists,apropertythatis
characteristic of allosteric agonists acting on 7 nAChRs (Fig.
6D). This supports the conclusion that 2,3,5,6MP-TQS and
2,4,6MP-TQS are binding at the previously identified trans-
membrane allosteric site (17, 25) and should be classified as
SAMs.
Influence of the Transmembrane M253L Mutation—Recent
studies have proposed that 7-selective PAMs and allosteric
agonistscanactviaatransmembranebindingsite(17,25).One
of the lines of evidence supporting this proposal is that poten-
tiation by TQS and also activation by 4BP-TQS is not observed
with 7 receptors containing the transmembrane mutation
M253L (17). In contrast, M253L has been shown to have no
significant effect on activation by the conventional orthosteric
agonist acetylcholine (17, 25).
The effect of the M253L mutation on activation by the six
allosteric agonists (2,3MP-TQS, 2,3,4MP-TQS, 2,3,4,5MP-
TQS, 2,4MP-TQS, 3,4MP-TQS, and 3,4,5MP-TQS) was exam-
ined. In all cases, the M253L mutation caused complete loss of
agonist activation. In addition, the effect of the M253L muta-
tion on allosteric potentiation by the eight PAMs (2MP-TQS,
2,3,4,6MP-TQS, 2,3,5MP-TQS, 2,4,5MP-TQS, 2,5MP-TQS,
3MP-TQS,3,5MP-TQS,andPentaMP-TQS)wasexamined.As
has been reported previously for potentiation by TQS (17), the
M253L mutation caused a complete loss of PAM activity with
all of these compounds. The simplest explanation for these
findingsmaybethatallofthesecompounds(allostericagonists
and PAMs in the series of methyl-substituted compounds) act
via a shared allosteric binding site, as has been proposed previ-
ously for TQS (a type II PAM) and 4BP-TQS (an allosteric ago-
nist) (17).
The effect of the M253L mutation was also examined on
those compounds that act as antagonists of acetylcholine (2,3,
6MP-TQS and 2,6MP-TQS) (Fig. 5D). Responses evoked by an
EC50concentrationofacetylcholine(100M)wereinhibitedby
64  4.0% with 2,3,6MP-TQS and by 73  1.7% with 2,6MP-
TQS.Theselevelsofinhibitionarenotsignificantlydifferentto
that observed with wild-type 7 nAChRs (Student’s t test, p 
FIGURE 4. Pharmacological properties of type II PAMs on 7 nAChRs
expressedinX. laevisoocytes.A,representativerecordingsareshownillus-
tratingresponsestotheapplicationofacetylcholine(100M)andamaximal
concentration of the PAM (100 M) preapplied for 10 s and then co-applied
with acetylcholine (100 M). Solid horizontal lines indicate the application of
acetylcholine,anddottedhorizontallinesindicatetheapplicationofthePAM.
Responses have been normalized to their peak response. B, concentration-
responsedataarepresentedforarangeofconcentrationsof2MP-TQS(open
triangles),2,3,5MP-TQS(opensquares),and3,5MP-TQS(crosses)onresponses
evokedbyasubmaximal(EC50)concentrationofacetylcholine(100M)with
wild-type 7 nAChRs. The PAM was preapplied for 10 s and then co-applied
with acetylcholine (100 M). Data are means  S.E. of at least three indepen-
dentexperiments,eachfromdifferentoocytes.Dataarenormalizedtoasub-
maximal (EC50) concentration of acetylcholine (100 M).
TABLE2
Pharmacological and kinetic properties of 7 nAChRs
Dataaremeansof3–28independentexperimentsS.E.Foldpotentiationrefersto
the increase in current, normalized to the mean response to a submaximal concen-
tration of acetylcholine (100 M) obtained from the same oocyte. Desensitization
rates correspond to the time constant for desensitization () in the continuous
presence of acetylcholine and, when appropriate, the PAM (significant differences
to desensitization rates with acetylcholine alone were determined by pairwise
Student’s t tests. NA, not applicable; ND, not determined.
Ligand EC50
Fold
potentiation
Desensitization
rate 
PAM
type
II I
M s
Acetylcholine 128  12 NA 1.5  0.1
2MP-TQS 16  1.3 39  7.5 16  3.2
a 
PentaMP-TQS 0.55  0.36 2.4  0.3 3.5  1.3 
2,3,4,6MP-TQS 9.1  2.0 2.3  0.3 1.1  0.1 
2,3,5MP-TQS 3.9  0.7 6.4  0.5 7.6  1.0
b 
2,4,5MP-TQS ND 11  2.7 4.0  0.2
b 
2,5MP-TQS ND 1.8  0.4 6.1  0.8
b 
3MP-TQS ND 22  2.1 33  9.9
a 
3,5MP-TQS 3.7  1.2 33  4.9 16  0.6
c 
a p  0.05.
b p  0.01.
c p  0.001.
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ated so as to introduce into the nAChR 7 subunit the amino
acid occurring at the analogous position in the mouse 5-HT3A
subunit(17,25).Forthisreason,theeffectof2,3,6MP-TQSand
2,6MP-TQS was examined on the mouse 5-HT3A subunit
expressed in oocytes. A maximal concentration of either
2,3,6MP-TQS or 2,6MP-TQS was preapplied and then co-ap-
plied with the 5-HT3 receptor (5-HT3R) agonist 1-(3-chloro-
phenyl)biguanide hydrochloride (CPBG) (1 M). Both TQS
compounds resulted in inhibition of responses evoked by
CPBG (Fig. 5D). The finding that 2,3,6MP-TQS and 2,6MP-
TQS act as inhibitors of both 7 nAChRs and 5-HT3R may
explainwhytheM253Lmutationin7hasnosignificanteffect
on allosteric modulation by 2,3,6MP-TQS or 2,6MP-TQS but
hasadramaticeffectonmodulationbyotherchemicallysimilar
allosteric modulators.
Radioligand Binding—The dramatic effect of the M253L
mutation on those methyl-substituted compounds displaying
agonist or PAM activity helps to provide support for the con-
clusionthatthesecompoundsmayactatapreviouslyproposed
transmembraneallostericsite(17,25).Incontrast,thecommon
inhibitory effect of 2,3,6MP-TQS and 2,6MP-TQS on 7
nAChRs and on 5-HT3A receptors means that no conclusions
canbemadefromstudieswiththeM253Lmutationconcerning
the two methyl-substituted compounds that display antagonist
effects on responses evoked by acetylcholine. Our working
hypothesis is that all of the structurally similar methyl-substi-
tuted compounds examined in this study are likely to interact
with a broadly similar allosteric site on the 7 nAChR, as dis-
cussed previously for other related compounds (17, 24). A con-
sequence of this hypothesis would be that the antagonism of
acetylcholine-evoked responses that has been observed with
2,3,6MP-TQS and 2,6MP-TQS is due to a noncompetitive
mechanism of action. With the aim of testing this hypothesis,
we examined the ability of methyl-substituted compounds to
displace the binding of an orthosteric radioligand ([
3H]-bun-
FIGURE 5. Pharmacological properties of antagonists (NAMs) on human 7 nAChRs and mouse 5HT3ARs expressed in X. laevis oocytes. A, represent-
ativerecordingsareshownillustratingresponseswithwild-type7.Inthetoppanel,Orthostericagonistindicatestheapplicationofacetylcholine(100M)and
amaximalconcentrationoftheantagonist(200M)preappliedfor10sandthenco-appliedwithacetylcholine(100M).Inthebottompanel,Allostericagonist
indicatestheapplicationof2,4MP-TQS(10M)andamaximalconcentrationoftheantagonist(200M)preappliedfor10sandthenco-appliedwith2,4MP-TQS
(10M).Solidhorizontallinesindicatetheapplicationoftheagonist,anddottedhorizontallinesindicatetheapplicationoftheNAM.B,concentration-response
data are presented illustrating the ability of 2,3,6MP-TQS (filled circles) and 2,6MP-TQS (open triangles) to inhibit responses evoked by a submaximal (EC50)
concentration of acetylcholine (100 M) on wild-type 7. The antagonist was preapplied for 10 s and then co-applied with acetylcholine (100 M). Data are
meansS.E.ofatleastthreeindependentexperiments,eachfromdifferentoocytes.Dataarenormalizedtoasubmaximal(EC50)concentrationofacetylcho-
line(100M).C,both2,3,6MP-TQSand2,6MP-TQSarenoncompetitiveantagonistsofacetylcholine.Concentration-responsedataarepresentedforarangeof
concentrations of acetylcholine acting on wild-type 7 nAChRs in either the absence (filled circles) or presence of 20 M 2,3,6MP-TQS (open circles)o r4 0M
2,6MP-TQS (open triangles). In all cases the antagonist was preapplied for 10 s and then co-applied with acetylcholine. Data are means  S.E. of at least three
independentexperiments,eachfromdifferentoocytes.Dataarenormalizedtoacetylcholine(3mM).D,inthetoppanels,representativerecordingsareshown
illustrating responses on 7
M253L to the application of acetylcholine (100 M)( left panel) and a maximal concentration of the antagonist (200 M) preapplied
for10sandthenco-appliedwithacetylcholine(100M)(rightpanel).Inthebottompanels,thesameprotocolwasusedforthe5-HT3AreceptorsexceptCPBG
(1M)wasusedastheagonistinsteadofacetylcholine.SolidhorizontallinesindicatetheapplicationofCPBG,anddottedhorizontallinesindicatetheapplication
of the PAM.
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3H]-bungarotoxin
binding was observed with any of the 19 methyl-substituted
compounds, even at the maximum concentration tested (100
M; ANOVA; p  1.0). Results obtained from competition
binding studies with 2,3,6MP-TQS and 2,6MP-TQS are illus-
trated in Fig. 7. This suggests that none of the methyl-substi-
tuted compounds bind competitively at the orthosteric nico-
tinic ligand-binding site. In contrast, as has been reported
previously (38), the competitive antagonist MLA causes com-
plete displacement of [
3H]-bungarotoxin from 7 nAChRs
(IC50  37  4.8 nM; Fig. 7). This provides support for our
conclusion that the antagonism of acetylcholine-evoked re-
sponses by 2,3,6MP-TQS and 2,6MP-TQS is by a noncompet-
itive (allosteric) mechanism and that all of the methyl-substi-
tuted compounds examined in this study act at a site distinct
from the conventional orthosteric binding site. It is also con-
sistent with our evidence that the antagonism of acetylcholine-
evoked responses by 2,3,6MP-TQS and 2,6MP-TQS is not sur-
mountable (Fig. 5C).
DISCUSSION
In the present study, the pharmacological properties of 19
methyl-substituted compounds have been examined. Evidence
has been obtained indicating that six of these compounds
(2,3MP-TQS, 2,3,4MP-TQS, 2,3,4,5MP-TQS, 2,4MP-TQS,
3,4MP-TQS, and 3,4,5MP-TQS) act as allosteric agonists of 7
nAChRs. Previous studies (24, 25) have provided evidence that
similar compounds (for example 4BP-TQS) interact with an
intrasubunit transmembrane cavity in 7 nAChRs (17, 24). It
seems plausible that the allosteric agonists examined in this
studyactviaasimilarsiteandbyasimilarmechanismofaction.
Severalofthecompoundsexaminedinthepresentstudylack
allosteric agonist activity but cause dramatic potentiation of
responses evoked by acetylcholine (PAM activity). Based on
their effect on the rate of agonist-evoked desensitization, com-
pounds were identified that fulfill the criteria of both type I
PAMs (which have no effect on receptor desensitization) and
type II PAMs (which cause a slowing of desensitization were
seen within the series). Two of the compounds examined
(2,3,4,6MP-TQS and PentaMP-TQS) resembled type I PAMs,
FIGURE 6. Pharmacological properties of SAMs on 7 nAChRs expressed
in X. laevis oocytes. A, representative recordings are shown illustrating
responsestotheapplicationofacetylcholine(100M)(leftpanel)andamax-
imal concentration of the SAM (100 M) preapplied for 10 s and then co-ap-
plied with acetylcholine (100 M)( right panel). B, representative recordings
arealsoshownillustratingresponsestotheapplicationof2,4MP-TQS(10M)
(left panel) and a maximal concentration of the SAM (100 M) preapplied for
10sandthenco-appliedwith2,4MP-TQS(100M)(rightpanel).Solidhorizon-
tal lines indicate the application of acetylcholine, and dotted horizontal lines
indicate the application of the SAM. C, concentration-response data are pre-
sentedillustratingtheabilityof2,4,6MP-TQStohavenoeffectonasubmaxi-
mal (EC50) concentration of acetylcholine (100 M)(  ) but to inhibit
responses evoked by a submaximal (EC50) concentration of 2,4MP-TQS (10
M)( ●). The compound was preapplied for 10 s and then co-applied with
either agonist. Data are means  S.E. of at least three independent experi-
ments, each from different oocytes. Data are normalized to a submaximal
(EC50)concentrationofeitheracetylcholine(100M)or2,4MP-TQS(10M).D,
the 7 nAChR transmembrane mutation L247T converts SAMs (2,3,5,6MP-
TQS and 2,4,6MP-TQS) into agonists. Representative recordings are shown
illustrating responses to the application of acetylcholine (10 M)( left panel),
2,3,5,6MP-TQS (10 M)( middle panel), and 2,4,6MP-TQS (10 M)( right panel)
on7
L247TnAChRs.Solidhorizontallinesindicatetheapplicationofacetylcho-
line, and dotted horizontal lines indicate the application of the SAM.
FIGURE 7. Competition radioligand binding on tsA201 cells transiently
co-transfected with human 7 nAChR cDNA and C. elegans RIC-3 cDNA.
Equilibriumradioligandbindingwasperformedwith[
3H]-bungarotoxin(10
nM) in the presence of varying concentrations of competing ligands (MLA or
allosteric modulators). No significant displacement of [
3H]-bungarotoxin
was observed with any of the 19 methyl-substituted compounds up to the
maximum texted (100 M). (Note that for simplicity, data are shown only for
two allosteric modulators (2,3,6MP-TQS and 2,6MP-TQS).) In contrast to the
findings with allosteric modulators, complete displacement of [
3H]-bunga-
rotoxin was observed with the orthosteric ligand MLA. Data are means of
triplicate samples from a single experiment, from three independent experi-
ments  S.E. Data are normalized to the maximal [
3H]-bungarotoxin
binding.
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2,4,5MP-TQS, 2,5MP-TQS, 3MP-TQS, and 3,5MP-TQS)
resembledtypeIIPAMs.Compoundsbelongingtobothgroups
ofPAMwereeffectiveinshiftingthepotencyofacetylcholineto
the left and increasing the maximum efficacies, a phenomenon
that is characteristic of nAChR PAMs (15, 39–41).
Work described here and elsewhere supports the conclusion
that allosteric agonists and PAMs of 7 nAChRs can bind to a
common transmembrane site (25, 26). This is supported by
evidencethattheeffectsofbothallostericagonistsandofPAMs
can be blocked completely by a single point mutation (M253L)
located in the transmembrane region, a mutation that has no
significant effect on agonist activation by the orthosteric ago-
nist acetylcholine (17, 25).
Two of the compounds examined in this series (2,3,6MP-
TQS and 2,6MP-TQS) lacked allosteric agonist activity but
caused dramatic inhibition of responses evoked by acetylcho-
line and also of responses evoked by an allosteric agonist
(2,4MP-TQS). When these compounds were examined on the
7
M253LnAChR,themutationwasfoundtohavenosignificant
effect on the level of inhibition by these compounds. However,
the M253L mutation was generated so as to introduce into the
nAChR 7 subunit the amino acid occurring at the analogous
position in the mouse 5-HT3A subunit (17, 25). Our finding
that responses evoked by the orthosteric agonist CPBG on
5-HT3Rswereinhibitedby2,3,6MP-TQSand2,6MP-TQSmay
explain why the M253L mutation had no effect on the antago-
nistactivityofthesecompoundson7nAChRs.Thisisbecause
the M253L mutation was designed to change the existing
methionine in 7 to the corresponding amino acid (leucine) at
the analogous position in the mouse 5-HT3A subunit (25).
Evidence to support the conclusion that these antagonists
bindnoncompetitivelywithrespecttoacetylcholineisprovided
by data demonstrating that the antagonism by 2,3,6MP-TQS
and 2,6MP-TQS is not surmountable (Fig. 5C). In addition,
competition radioligand binding data provide further support
for the conclusion that both 2,3,6MP-TQS and 2,6MP-TQS
bind at a site other than the conventional orthosteric binding
site. The structural similarity between 2,3,6MP-TQS and
2,6MP-TQS with that of other compounds differing only in
methyl substitution of a phenyl ring (including allosteric ago-
nists and PAMs) suggests that the most likely explanation for
the inhibition of acetylcholine responses is that these com-
pounds are binding noncompetitively with respect to acetyl-
cholineandatacommonoroverlappingtransmembranesiteto
that of the allosteric agonists and PAMs examined here.
As others have done previously (42, 43), we have used the
term“silentallostericmodulator”(SAM)todenotecompounds
that interact with an allosteric site but that do not exert a mod-
ulatory effect on responses to the orthosteric agonist (i.e. nei-
ther a positive or negative allosteric effect) and that do have
modulatory effects on compounds that interact at the same
allosteric site. Two of the compounds examined in this study
(2,3,5,6MP-TQS and 2,4,6MP-TQS) exhibited no allosteric
agonistactivityandneitherpotentiatednorinhibitedresponses
evoked by acetylcholine. They did, however, act as antagonists
of allosteric agonists. The simplest explanation for this obser-
vation is that 2,3,5,6MP-TQS and 2,4,6MP-TQS interact with
the same allosteric site as allosteric agonists such as 4MP-TQS
(17, 24) and can therefore be considered as being SAMs. The
factthatneithercompoundcauseddisplacementof[
3H]-bun-
garotoxin from its orthosteric binding site supports this con-
clusion. In this respect, they can be considered as acting in a
manner that is analogous to previously described SAMs of G
protein-coupledreceptors(42,43).Similarly,ithasbeenshown
previouslythat7nAChRPAMssuchasTQScanactasantag-
onists of responses evoked by allosteric agonists such as 4BP-
TQS (24, 35), presumably because they are binding competi-
tively to a common site. The two compounds that acted as
SAMs on wild-type 7 nAChRs (2,3,5,6MP-TQS and 2,4,6MP-
TQS) both displayed agonist activity on mutant 7
L247T
nAChRs. The L247T mutation is known to have a higher fre-
quencyofspontaneousopenings(44),soitispossiblethatbind-
ingof2,3,5,6MP-TQSor2,4,6MP-TQSstabilizestheopencon-
formation of the receptor, resulting in agonist activity.
Synthesisofthemethyl-substitutedcompoundsintheInCl3-
catalyzed reaction can potentially result in of the formation of
up to four different diastereoisomers. Typically, however, only
twoisomersareobserved,classifiedascis-cisorcis-transonthe
basis of the relative stereochemistry of the three stereocenters
on the isoquinoline ring (Fig. 1). The stereochemistry of the
major isomer of each of the methyl-substituted compounds
describedinthisstudywasassignedonthebasisofthecoupling
constantsobservedinthe
1HNMR(seesupplementalmaterials
fordetails).Inmostcases,thecis-cis-isomerwasobtainedasthe
major product, but reactions with more hindered benzalde-
hydes, containing two methyl groups ortho to the aldehyde
group,gavethecis-trans-isomerasthemajorproduct(Fig.1).It
is likely that the presence of these two methyl groups leads the
corresponding imine to adopt a very different conformation to
avoid steric clash between the imine and the nearby methyl
groups.Thisinturnislikelytoraisetheenergyofthetransition
state,leadingtotheformationoftherelativelyhinderedcis-cis-
isomer during the cyclization reaction. As a consequence, the
formation of the cis-trans-isomer becomes preferred to the
extent that it is the sole product observed with these more hin-
dered imines. Interestingly, all of the compounds that have
been classified as allosteric agonists or as type II PAMs were
found to be cis-cis-diastereoisomers, whereas all of the NAMs,
SAMs, and type I PAMs were cis-trans-diastereoisomers.
Whereas we have previously obtained evidence that the size
of the group attached to position 4 of the phenyl ring of TQS
compoundscaninfluenceallostericproperties(24),ourpresent
findings indicate the role of groups attached at positions 2 and
6.Theseconclusionsabouttheimportanceofpositions2and6
are also consistent with data obtained from all of the com-
poundssimilartoTQSthatwehaveexaminedpreviously,allof
which are either allosteric agonists or type II PAMs (17). All of
thesecompoundarecis-cis-diastereoisomers,andnonecontain
substituentsatbothpositions2and6(17).Ourfindingsarealso
consistent with recent studies demonstrating that the cis-cis-
(	)-enantiomerof4BP-TQS(GAT107)isactiveasanallosteric
agonist (45, 46).
Inconclusion,wehavesynthesizedaseriesof19compounds,
containing all possible variations of methyl substitution at a
single aromatic ring. Whereas previous studies of compounds
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tericagonistsortypeIIPAMs(15,17,24),studiesconductedwith
thisseriesof19methyl-substitutedcompoundshaverevealedfive
distinct pharmacological effects on 7 nAChRs. In addition to
allosteric agonists and type II PAMs, we have identified type I
PAMsandalsocompoundsthatreduceagonist-evokedresponses
andcanbeconsideredasNAMs(are,alternatively,asnoncompet-
itive antagonists). Finally, compounds have been identified that
havenosignificanteffectonorthostericagonist-evokedresponses
but block responses to allosteric agonists (classified as SAMs). In
summary,the19methyl-substitutedcompoundsexaminedinthis
study (Fig. 1) can be classified in one of five categories: allosteric
agonists (7 of the 19 compounds), type I PAMs (2 compounds),
type II PAMs (6 compounds), NAMs (2 compounds), or SAMs (2
compounds). The data we have obtained are consistent with all of
these compounds interacting with a common transmembrane
allosteric site, as has been proposed previously for other allosteric
modulators of 7 nAChRs (17, 24–26).
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